Sumitomo Pharma Co., Ltd.: Business Overview, Financials & Competitive Analysis
Sumitomo Pharma Co., Ltd. scores 8/10 on the AskCyborg Cyborg Score (Strong). Sumitomo Pharma is capitalizing on blockbuster North American products while cost discipline and restructuring strengthen profitability, though domestic headwinds and pipeline execution risks warrant caution. The company reported a dramatic 408.5% year-over-year increase in core operating profit, primarily driven by strong sales growth in North America and effective.
What is Sumitomo Pharma Co., Ltd.'s industry? Sumitomo Pharma Co., Ltd. (sumitomo-pharma.com) operates in Pharmaceuticals - Specialty & Generic. AskCyborg classifies Sumitomo Pharma Co., Ltd. under Pharmaceuticals - Specialty & Generic in its company registry.
Sumitomo Pharma manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. As a specialty and generic drug manufacturer, the company's vast majority of sales ar...
Cyborg Score thesis
Sumitomo Pharma is capitalizing on blockbuster North American products while cost discipline and restructuring strengthen...
Read the full analyst-debate transcript →Get the Latest Sumitomo Pharma Co., Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSumitomo Pharma Co., Ltd. Overview
Pro stress-test →Sumitomo Pharma manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. As a specialty and generic drug manufacturer, the company's vast majority of sales are generated in North America, followed by Japan. The company has demonstrated exceptional recent momentum with record profitability driven by blockbuster North American products.
Strategic Profile
Pro stress-test →Sumitomo maintains a focus on cardiovascular/diabetes, psychiatry & neurology, and specialty areas. The company restructured its domestic sales force to focus on product expertise and established new sales partnerships in CNS and diabetes/obesity areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding research, development, manufacturing, and marketing capabilities.
Competitive Landscape
Pro stress-test →Chugai Pharmaceutical is one of Sumitomo Pharma's 27 competitors. The company competes in specialty and generic pharmaceuticals across multiple therapeutic areas, with key North American competitors in oncology and CNS disorders. Sumitomo differentiates through strategic product partnerships (notably with Pfizer for ORGOVYX) and emerging pipeline assets in regenerative medicine.
Industry Context
Sumitomo Pharma Co., Ltd. operates in Pharmaceuticals - Specialty & Generic.
Key facts
Founded: 1897 · Headquarters: Osaka, Japan · Employees: 4,980 · Revenue: $2.98B · Market cap: $6.0B